Skip to main content
. 2012 Nov 14;7(11):e48991. doi: 10.1371/journal.pone.0048991

Figure 3. Random modified intention to treat meta-analysis of overall cancer risk when TNF-α antagonists are used at doses in line with New Drug Approval.

Figure 3

Abbreviations: ADA, adalimumab; CTZ, certolizumab pegol; ETN, etanercept; GMM, golimumab; IFX, infliximab; 95% CI, 95% confidence interval.